» Articles » PMID: 24053644

Nrf2 Regulates Angiogenesis: Effect on Endothelial Cells, Bone Marrow-derived Proangiogenic Cells and Hind Limb Ischemia

Abstract

Aims: Nuclear factor E2-related factor 2 (Nrf2), a key cytoprotective transcription factor, regulates also proangiogenic mediators, interleukin-8 and heme oxygenase-1 (HO-1). However, hitherto its role in blood vessel formation was modestly examined. Particularly, although Nrf2 was shown to affect hematopoietic stem cells, it was not tested in bone marrow-derived proangiogenic cells (PACs). Here we investigated angiogenic properties of Nrf2 in PACs, endothelial cells, and inflammation-related revascularization.

Results: Treatment of endothelial cells with angiogenic cytokines increased nuclear localization of Nrf2 and induced expression of HO-1. Nrf2 activation stimulated a tube network formation, while its inhibition decreased angiogenic response of human endothelial cells, the latter effect reversed by overexpression of HO-1. Moreover, lack of Nrf2 attenuated survival, proliferation, migration, and angiogenic potential of murine PACs and affected angiogenic transcriptome in vitro. Additionally, angiogenic capacity of PAC Nrf2(-/-) in in vivo Matrigel assay and PAC mobilization in response to hind limb ischemia of Nrf2(-/-) mice were impaired. Despite that, restoration of blood flow in Nrf2-deficient ischemic muscles was better and accompanied by increased oxidative stress and inflammatory response. Accordingly, the anti-inflammatory agent etodolac tended to diminish blood flow in the Nrf2(-/-) mice.

Innovation: Identification of a novel role of Nrf2 in angiogenic signaling of endothelial cells and PACs.

Conclusion: Nrf2 contributes to angiogenic potential of both endothelial cells and PACs; however, its deficiency increases muscle blood flow under tissue ischemia. This might suggest a proangiogenic role of inflammation in the absence of Nrf2 in vivo, concomitantly undermining the role of PACs in such conditions.

Citing Articles

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.

Rojo A, Buttari B, Cadenas S, Carlos A, Cuadrado A, Falcao A Redox Biol. 2024; 79():103464.

PMID: 39709790 PMC: 11733061. DOI: 10.1016/j.redox.2024.103464.


The Role of the Nrf2 Pathway in Airway Tissue Damage Due to Viral Respiratory Infections.

Kombe Kombe A, Fotoohabadi L, Nanduri R, Gerasimova Y, Daskou M, Gain C Int J Mol Sci. 2024; 25(13).

PMID: 39000157 PMC: 11241721. DOI: 10.3390/ijms25137042.


Dysregulated VEGF/VEGFR-2 Signaling and Plexogenic Lesions in the Embryonic Lungs of Chickens Predisposed to Pulmonary Arterial Hypertension.

Ye L, Liu R, Li Q, Zhou C, Tan X Int J Mol Sci. 2024; 25(8).

PMID: 38674074 PMC: 11049811. DOI: 10.3390/ijms25084489.


Effects of Supplementation with Microalgae Extract from (Mi136) to Support Benefits from a Weight Management Intervention in Overweight Women.

Dickerson B, Maury J, Jenkins V, Nottingham K, Xing D, Gonzalez D Nutrients. 2024; 16(7).

PMID: 38613023 PMC: 11013338. DOI: 10.3390/nu16070990.


Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer.

Bae T, Hallis S, Kwak M Exp Mol Med. 2024; 56(3):501-514.

PMID: 38424190 PMC: 10985007. DOI: 10.1038/s12276-024-01180-8.


References
1.
He T, Peterson T, Holmuhamedov E, Terzic A, Caplice N, Oberley L . Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol. 2004; 24(11):2021-7. DOI: 10.1161/01.ATV.0000142810.27849.8f. View

2.
Wajant H . The role of TNF in cancer. Results Probl Cell Differ. 2009; 49:1-15. DOI: 10.1007/400_2008_26. View

3.
Losordo D, Dimmeler S . Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation. 2004; 109(22):2692-7. DOI: 10.1161/01.CIR.0000128596.49339.05. View

4.
Yamaguchi J, Kusano K, Masuo O, Kawamoto A, Silver M, Murasawa S . Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003; 107(9):1322-8. DOI: 10.1161/01.cir.0000055313.77510.22. View

5.
Napoli C, Hayashi T, Cacciatore F, Casamassimi A, Casini C, Al-Omran M . Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis. 2010; 215(1):9-22. DOI: 10.1016/j.atherosclerosis.2010.10.039. View